Quantcast

Latest PD-1 Stories

2014-09-10 12:28:10

The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept. 10, 2014 /PRNewswire/ -- The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the...

2014-06-30 12:29:20

Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This impressive...

2014-06-01 08:20:34

NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers. The results were presented today at the 2014 ASCO...

2014-03-26 11:23:23

Presentations at the 4th European Lung Cancer Conference A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy –treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France. However a...

2014-03-05 10:57:36

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments. Patients who showed responses to the drug, nivolumab (anti-PD-1;...

2014-02-13 04:20:48

Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES, France and BANGALORE, India, February 13, 2014 /PRNewswire/ -- Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and...

Science Magazine Compiles Top Ten Breakthroughs Of 2013
2013-12-20 06:01:28

April Flowers for redOrbit.com - Your Universe Online At the end of each year, Science combs through the scientific breakthroughs of the past year and compiles a top ten list. This year, the list includes major breakthroughs in solar cell technologies, genome-editing techniques and vaccine design strategies, to name a few. But the number one breakthrough came in the form of cancer immunotherapy. 2013 saw a striking change in the cancer research community in the form of a strategy that...

2013-10-23 23:01:18

Society for Immunotherapy of Cancer Annual Meeting & Associated Programs - November 7-10, 2013 in National Harbor, MD Milwaukee, WI (PRWEB) October 23, 2013 Hear first-hand the latest cutting-edge cancer immunotherapy research straight from the experts at SITC 2013, November 7-10, 2013 at the Gaylord National Hotel and Convention Center in National Harbor, MD. Members of the media can register free of charge for a press pass, granting access to exciting educational programs that...

2013-09-30 13:15:10

New results from a trial of an antibody that helps the immune system to recognize and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers. Presenting the most up-to-date data from 85 patients with non-small cell lung cancer in a large, phase I clinical trial of an experimental drug called MPDL3280A, Professor Jean-Charles Soria told the 2013 European Cancer Congress (ECC2013) today (Sunday): "This is the first study to suggest a...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.